Tag: ThromboGenics

July 10, 2017 Off

BioInvent and ThromboGenics amending long-standing monoclonal antibody development agreement

BioInvent International and ThromboGenics have agreed to amend their long-standing agreement, which covers the co-development of the novel anti-PlGF monoclonal antibody products TB-403 and THR-317.

April 20, 2017 Off

Bicycle Therapeutics to receive milestone from eye drug development agreement

By Dino Mustafić

ThromboGenics will pay preclinical milestone to Bicycle Therapeutics in connection with the advancement of a Bicycle (bicyclic peptide) into preclinical development for the treatment of diabetic macular edema.